Quarterly report · Q2
4272.TEDINET S100PHL2
Period2022-04-01 → 2022-09-30
Filed2022-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥102.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥184.8bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥88.8bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥13.6bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥10.9bn | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥16.6bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥23.2bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥11.8bn | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥16.4bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥13.0bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥11.3bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥17.2bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥9.2bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥11.3bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥9.3bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥329.5bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥315.5bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥302.0bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥70.3bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥69.0bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥259.2bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥246.4bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥233.5bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥41.9bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥38.5bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥52.6bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥53.0bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥50.4bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥47.5bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥12.0bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥23.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥14.4bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥9.2bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥10.6bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥5.6bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥6.2bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥11.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥6.4bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥67.04 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥31.63 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥101.7 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥54.27 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥23.35 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥67.02 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥101.65 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥54.26 | 2021-04-01 → 2021-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 78.4% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 77.8% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 77.0% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 52
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-09-30 | ¥4.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-09-30 | ¥4.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥55m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-09-30 | ¥899m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥137m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥137m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥3.7bn |
| jpcrp040300-q2r_E00836-000Functional Chemicalsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥46.1bn |
| jpcrp040300-q2r_E00836-000Functional Chemicalsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥46.0bn |
| jpcrp040300-q2r_E00836-000Functional Chemicalsreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥82m |
| jpcrp040300-q2r_E00836-000Functional Chemicalsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥7.8bn |
| jpcrp040300-q2r_E00836-000Medicinereportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥25.3bn |
| jpcrp040300-q2r_E00836-000Medicinereportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥25.3bn |
| jpcrp040300-q2r_E00836-000Medicinereportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥0 |
| jpcrp040300-q2r_E00836-000Medicinereportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥4.5bn |
| jpcrp040300-q2r_E00836-000Safety Systemsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥26.7bn |
| jpcrp040300-q2r_E00836-000Safety Systemsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥26.7bn |
| jpcrp040300-q2r_E00836-000Safety Systemsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥4.0bn |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥98.2bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥98.1bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥82m |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥16.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥102.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥102.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥137m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥17.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2021-09-30 | ¥4.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2021-09-30 | ¥4.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥51m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2021-09-30 | ¥919m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥123m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥123m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥3.4bn |
| jpcrp040300-q2r_E00836-000Functional Chemicalsreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥37.7bn |
| jpcrp040300-q2r_E00836-000Functional Chemicalsreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥37.6bn |
| jpcrp040300-q2r_E00836-000Functional Chemicalsreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥71m |
| jpcrp040300-q2r_E00836-000Functional Chemicalsreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥6.1bn |
| jpcrp040300-q2r_E00836-000Medicinereportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥25.5bn |
| jpcrp040300-q2r_E00836-000Medicinereportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥25.5bn |
| jpcrp040300-q2r_E00836-000Medicinereportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥0 |
| jpcrp040300-q2r_E00836-000Medicinereportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥4.1bn |
| jpcrp040300-q2r_E00836-000Safety Systemsreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥21.6bn |
| jpcrp040300-q2r_E00836-000Safety Systemsreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥21.6bn |
| jpcrp040300-q2r_E00836-000Safety Systemsreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥3.2bn |
| —segment total | revenue | 2021-04-01 → 2021-09-30 | ¥84.8bn |
| —segment total | revenue external | 2021-04-01 → 2021-09-30 | ¥84.8bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥71m |
| —segment total | segment profit | 2021-04-01 → 2021-09-30 | ¥13.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-09-30 | ¥89.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-09-30 | ¥88.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥123m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-09-30 | ¥14.3bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 583
| Item | Context | Value | Unit |
|---|---|---|---|
| Depreciation ga | CurrentYTDDuration | 325000000 | JPY |
| Research and development expenses sga | Prior1YTDDuration | 5848000000 | JPY |
| Research and development expenses sga | CurrentYTDDuration | 6058000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E00836-000FunctionalChemicalsReportableSegmentsMember | 37612000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E00836-000MedicineReportableSegmentsMember | 25534000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E00836-000SafetySystemsReportableSegmentsMember | 21618000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReportableSegmentsMember | 84765000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 4074000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 88840000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 88840000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E00836-000FunctionalChemicalsReportableSegmentsMember | 71000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E00836-000MedicineReportableSegmentsMember | 0 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E00836-000SafetySystemsReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReportableSegmentsMember | 71000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 51000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 123000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -123000000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00836-000FunctionalChemicalsReportableSegmentsMember | 37684000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00836-000MedicineReportableSegmentsMember | 25534000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00836-000SafetySystemsReportableSegmentsMember | 21618000000 | JPY |
| Net sales | Prior1YTDDuration_ReportableSegmentsMember | 84837000000 | JPY |
| Net sales | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 4126000000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 88964000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -123000000 | JPY |
| Net sales | Prior1YTDDuration | 88840000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00836-000FunctionalChemicalsReportableSegmentsMember | 6074000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00836-000MedicineReportableSegmentsMember | 4115000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00836-000SafetySystemsReportableSegmentsMember | 3169000000 | JPY |
| Operating income | Prior1YTDDuration_ReportableSegmentsMember | 13360000000 | JPY |
| Operating income | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 919000000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 14279000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -3376000000 | JPY |
| Operating income | Prior1YTDDuration | 10902000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E00836-000FunctionalChemicalsReportableSegmentsMember | 46023000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E00836-000MedicineReportableSegmentsMember | 25334000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E00836-000SafetySystemsReportableSegmentsMember | 26742000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReportableSegmentsMember | 98100000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 4628000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 102728000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 102728000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00836-000FunctionalChemicalsReportableSegmentsMember | 82000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00836-000MedicineReportableSegmentsMember | 0 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00836-000SafetySystemsReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | 82000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 55000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 137000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -137000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |